#### 1 Protocol For Human Evaluation of Artificial Intelligence Chatbots in Clinical

# 2 Consultations

- 3 Edwin Kwan-Yeung Chiu, MRCP(UK)<sup>a</sup>; Tom Wai-Hin Chung, FRCPath<sup>a</sup>.
- <sup>4</sup> <sup>a</sup>Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong,
- 5 Hong Kong, China.
- 6 Keywords: artificial intelligence, generative, large language model, chatbot, infectious
- 7 diseases, microbiology, consultation.
- 8 Running title: Protocol for Human Evaluation of AI chatbots in Clinical Consultations

# 9 Correspondence:

- 10 Tom Wai-Hin Chung, Department of Microbiology, Li Ka Shing Faculty of Medicine, The
- 11 University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.
- 12 Phone: (852) 22552409. Fax: (852) 28724555. E-mail: tomwhc@hku.hk. ORCID iD:
- 13 https://orcid.org/0000-0003-1780-821X.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 14 Abstract

#### 15 Background

Generative artificial intelligence (AI) technology has the revolutionary potentials to augment clinical practice and telemedicine. The nuances of real-life patient scenarios and complex clinical environments demand a rigorous, evidence-based approach to ensure safe and effective application.

#### 20 Methods

We present a protocol for the systematic evaluation of generative AI large language models (LLMs) as chatbots within the context of clinical microbiology and infectious disease consultations. We aim to critically assess the clinical accuracy, comprehensiveness, coherence, and safety of recommendations produced by leading generative AI models, including Claude 2, Gemini Pro, GPT-4.0, and a GPT-4.0-based custom AI chatbot.

# 26 **Discussion**

27 A standardised healthcare-specific prompt template is employed to elicit clinically impactful 28 AI responses. Generated responses will be graded by a panel of human evaluators, 29 encompassing a wide spectrum of domain expertise in clinical microbiology and virology and 30 clinical infectious diseases. Evaluations are performed using a 5-point Likert scale across four 31 clinical domains: factual consistency, comprehensiveness, coherence, and medical harmfulness. 32 Our study will offer insights into the feasibility, limitations, and boundaries of generative AI 33 in healthcare, providing guidance for future research and clinical implementation. Ethical 34 guidelines and safety guardrails should be developed to uphold patient safety and clinical 35 standards.

#### **36 INTRODUCTION**

37 With global aging population, ever increasing healthcare demands and the rapid evolution of 38 healthcare technologies, effective integration of artificial intelligence (AI) into clinical workflow and decision-making processes have become a focal point of research and debate. 39 40 Generative AI have demonstrated significant potentials in understanding natural language and 41 addressing cognitive tasks. (1) The prospects of generative AI replacing or augmenting 42 physician tasks, particularly in telemedicine where information exchange is primarily text-43 based, has prompted investigations into their practicality and safety in clinical consultations. 44 (2)

Preliminary investigations have demonstrated the potentials for AI in managing various 45 46 infectious disease syndromes (e.g., bloodstream infections and brain abscesses), however, 47 concerns remain about the reliability, safety, and ethics of the utilisation of generative AI in 48 clinical practices.(3-5) This study is among the first to systemically evaluate the state-of-the-49 art generative AI large language model (LLM) chatbots, including a custom AI chatbot (custom 50 bot) integrated with domain-specific medical literature. In addition, this study employs a novel 51 self-developed healthcare-specific prompt template purposely designed to examine AI chatbot 52 performances in complex real-life clinical scenarios. A unique dual-tier evaluation system that 53 includes both consultant-level specialists and non-specialist physicians is also implemented in 54 the evaluation process to offer a comprehensive assessment from multiple levels of domain 55 expertise and clinical practice.

The objective of this protocol is to critically assess the clinical accuracy, coherence, comprehensiveness, and safety of recommendations provided by AI chatbots. This research aims to contribute to the ongoing discourse on the role of generative AI in healthcare and to aid in the development of guidelines that ensure the safe and effective implementation of generative AI in clinical microbiology and infectious disease domains.

#### 61 MATERIALS AND METHODS

62 This project aims to evaluate the potential role of AI chatbots to assist clinicians by providing 63 immediate analysis and suggestions to enhance and augment daily clinical practice and 64 workflow. The protocol employs a universal standardised prompt template to compare between 65 AI chatbot responses based on real-life clinical scenarios and anonymised patient data. 66 Generated responses will be evaluated by a panel of practicing clinicians [specialists (n = 3); non-specialists (n = 3)] using a Likert scale. (6) Human evaluators will serve as domain experts 67 68 with specialist knowledge in clinical microbiology and virology, as well as internal medicine 69 and clinical infectious diseases (Fig 1).

## 70 Data source

During the pre-defined study period, real-life clinical consultation notes will be extracted retrospectively from the digital depository (in-house software) of the Department of Microbiology, Queen Mary Hospital (QMH), Hospital Authority. During the study period, 10 clinical consultation documents derived from four clinical microbiologists [specialists (n = 2)] and non-specialists (n = 2)] will be included consecutively.

For the inclusion criterion, only new in-patient consultation referrals received by the Department of Microbiology (QMH) during the study period will be included. As for exclusion criteria, duplicated consultations will be removed to limit redundancy and potential data skew. Follow-up consultations and reviews of the same clinical episode will be excluded to focus on initial management approach, diagnostic assessments, and treatment decisions. The inclusion and exclusion criteria are carefully designed to maintain clarity and data integrity and to ensure a well-defined analytical framework.

# 83 Data preprocessing

Data preprocessing will be conducted manually by E.K.Y.C and T.W.H.C. To maintain the authenticity of the clinical consultation notes, preprocessing procedures are designed to be

86 minimal, where the clinical context, syntax and written styles of the original documents are 87 retained as far as possible. Patient identifiable information is removed, and names of medical 88 institutions are excluded or anonymised. Medical terminologies are standardised, where 89 abbreviations and non-universal short forms are converted into their full terms (e.g., expanding abbreviations: from 'c/st' to 'culture', 'T/F' to 'pending results', 'CMV D+R-' to 90 91 'cytomegalovirus seropositive donor and seronegative recipient'). Moreover, appropriate International System (SI) of units are included for quantitative results to allow clear 92 93 interpretations (e.g., adding 'g/dL' to the values of haemoglobin). For chronological structuring, 94 relevant dates are included in the clinical scenarios. Lastly, to ensure structural uniformity 95 across all clinical scenarios, the contents are outlined systematically into five categories: "Basic 96 demographics & Underlying medical conditions", "Current admission", "Physical examination 97 findings", "Investigation results" and "Antimicrobials & Treatments".

# 98 **Prompt template**

99 A standardised, unconditional, zero-shot prompt template was developed for this study (Fig 2). 100 The prompt template begins with a system message that defined the behaviour of the AI 101 chatbots and prescribed the style of response within pre-defined boundaries. In this study, AI 102 chatbots were primed as "an artificial intelligence assistant with expert knowledge in clinical 103 medicine, infectious disease, clinical microbiology and virology".

All clinical scenarios will be processed as dedicated files along with the standardised prompt template. (7) Within the prompt template, the analytical process was broken down into clinically meaningful segments and sub-tasks, to allow a logical sequence of prompts, where the outputs permeate sequentially throughout the step-by-step process. (8, 9) At the end of the prompt, the AI chatbots were further instructed to follow the prompt instructions strictly to reinforce the specific model persona for the desired generated responses. (10) Output formats

110 were standardised throughout the prompt chain; where certain AI model(s) did not support 111 table generation, the outputs will be reformatted into lists.

#### 112 AI chatbots

113 AI chatbots will be accessed via Poe (Quora, California, U.S.), a third-party subscription-based

114 AI software platform. We will evaluate the responses generated from Claude 2 (Anthropic,

115 California, U.S.), Gemini Pro (Google DeepMind, London, U.K.), GPT-4.0 (OpenAI,

116 California, U.S.), and a custom bot based on GPT-4.0.

117 The custom bot was created through the "Create bot" function within the Poe interface. GPT-

118 4 was selected as the foundation model for the custom bot. Four widely recognised clinical

references were integrated into the knowledge base of the custom bot, which included: Török,

120 E., Moran, E. and Cooke, F. (2017) Oxford Handbook of Infectious Diseases and Microbiology.

121 Oxford University Press. (11); Mitchell, R.N., Kumar, V., Abbas A.K. and Aster, J.C. (2016).

122 Pocket Companion to Robbins & Cotran Pathologic Basis of Disease (Robbins Pathology).

123 Elsevier. (12); Sabatine, M.S. (2022) Pocket Medicine: The Massachusetts General Hospital

124 Handbook of Internal Medicine. Lippincott Williams & Wilkins. (13) and Gilbert, D.N.,

125 Chambers, H.F., Saag, M.S., Pavia, A.T. and Boucher, H.W. (editors) (2022) The Sanford

126 Guide to Antimicrobial Therapy 2022. Antimicrobial Therapy, Incorporated. (14) These

127 references aimed to provide domain-specific knowledge to inform the generated responses by

the custom bot.

The response variability of the AI chatbots were configured to the pre-determined temperature setting as defined by Poe, which were most applicable to the general user. Temperature, a hyperparameter in the generative AI model, determined the degree of randomness in its responses. A lower setting produced more predictable responses while a higher setting produced answers with greater variability and creativity. (15) The pre-set temperature configurations for the AI chatbots were Claude 2 at 0.5, GPT-4 at 0.35, and the custom bot at

135 0.35; whereas the exact temperature setting for Gemini Pro was not publicly available during 136 the assessment period. Each clinical scenario will be presented as a new chat using an 137 unconditional prompt to ensure unbiased outputs. All scenarios will be inputted by E.K.Y.C. 138 and processed on a prespecified date to ensure output consistency.

#### 139 Blinding, Randomisation and Data Compilation

The dataset will include 40 unique clinical scenarios that will be processed by four different AI chatbots (i.e., Claude 2, Gemini Pro, GPT-4.0 and the custom bot), resulting in 160 total outputs. All study authors (except E.K.Y.C.) and human evaluators will be blinded to the original author for the clinical scenarios and AI chatbot output.

144 Clinical case scenarios will be randomised at the input level, with the subsequent generated 145 responses further randomised at the analytical level to mitigate risk of evaluator biases. 146 Randomised clinical scenarios and corresponding AI chatbot output will be uploaded onto the 147 Qualtrics survey platform (Qualtrics, Utah, U.S.) for human evaluation and grading. Assigned 148 gradings will be recorded automatically by the survey platform for data compilation and 149 analysis.

#### 150 Human evaluation

151 Two groups of human evaluators will be invited to conduct the study. The first group will consist of consultant-level specialists (n = 3) in clinical microbiology and virology (pathology) 152 153 and infectious diseases (internal medicine). The second group will include non-specialist 154 resident trainees (n = 3) from the Department of Microbiology (QMH) and Department of 155 Medicine (Infectious Diseases unit; QMH). The selected groups of human evaluators will represent practicing clinicians from pathology and internal medicine. The panel will include 156 157 doctors at various stages of their medical careers, therefore offering diverse range of insights 158 into the analytical performance of AI chatbots in the clinical setting.

The evaluators will be presented with the clinical scenarios in random order and their corresponding AI chatbot-generated responses, which will also be randomised and anonymised. Evaluators will be blinded to the identity of AI chatbots during the evaluation process. They will be instructed to read the entire clinical scenario and each of the generated responses before grading. Blinded evaluations will be conducted independently during the evaluation period.

# 164 **Evaluation scale**

165 AI chatbot responses will be evaluated systematically using a 5-point Likert scale across four

166 clinically relevant domains: (1) factual consistency, (2) comprehensiveness, (3) coherence and

167 (4) medical harmfulness (Table). (6)

Factual consistency will be assessed by examining whether the information synthesised by the 168 169 AI chatbots are verifiable and factual, pertaining to the clinical data provided in the scenarios. 170 Comprehensiveness will be assessed by the degree to which the generated response 171 encapsulated all the necessary information required to fulfil the objectives specified in the 172 prompt template, ensuring a detailed and thorough analytical assessment. Coherence will be 173 evaluated based on the chatbot's ability to produce a logically structured and clinically 174 impactful analysis that adhered to the step-by-step guidance of the prompt template. Medical 175 harmfulness will consider the likelihood of the generated output to inflict patient harm, which encompassed recommending inappropriate investigations, suggesting harmful treatments, or 176 177 offering incorrect management strategies due to misinterpretation or erroneous fabrications 178 (e.g., hallucinations).

#### 179 OUTCOMES

180 The primary outcome will be the composite score comparisons between AI chatbots. Secondary 181 outcomes will include domain-level comparisons across generated responses, and correlation 182 analysis between composite scores and characteristics of clinical scenarios and AI chatbot 183 output.

#### 184 STATISTICAL ANALYSIS

#### 185 **Descriptive statistics**

186 Descriptive statistics will be presented as median (interquartile range, IQR) and mean (standard

- 187 deviation) values. (16, 17) The Shapiro-Wilk test will be employed to assess the normality of
- 188 the data distributions.

# 189 Internal consistency

190 The internal consistency of the Likert scale items—factual consistency, comprehensiveness,

191 coherence, and medical harmfulness—will be assessed using Cronbach's alpha coefficient.

192 This analysis ascertains whether the four domains collectively contribute to a single underlying

193 construct, therefore appropriate for creating a composite score. (16)

# 194 **Composite score evaluation**

195 Composite scores (range, 4-20) will be constructed by the summation of all four domains. 196 Differences in mean composite scores among chatbots will be examined using one-way 197 Analysis of Variance (ANOVA). Tukey's Honest Significant Difference (HSD) test will be 198 applied for post-hoc pairwise comparisons. (17, 18) Paired t-tests will be used for within-group 199 comparisons of composite scores between specialist and non-specialist evaluators.

# 200 **Domain-level evaluation**

At the domain level, Kruskal-Wallis H-test with Bonferroni correction will be used to compare median values across groups. This analysis is conducted for each domain variable to assess differences between AI chatbots. (19) Furthermore, we will evaluate the frequency of responses crossing critical thresholds—such as "insufficiently verified facts" in the factual consistency domain, or "substantially incoherent" in the coherence domain. Prevalence ratios will be computed to compare incidence rates between different generated responses. (20)

# 207 Correlation analysis

Pearson correlation coefficients will be calculated to investigate the relationship between composite scores and word counts from scenario inputs and the corresponding generated outputs. This investigates whether the quantity of text correlates with the quality as perceived through the composite scores.

#### 212 Statistical significance

213 A p-value of less than 0.05 will be considered statistically significant.

#### 214 Interrater reliability

Interrater reliability will be assessed using the Intraclass Correlation Coefficient (ICC) from a two-way random-effects model. This model accounts for the random selection of six evaluators from a larger pool of clinical microbiologists and infectious disease physicians, reflecting the generalisability of the reliability estimate to other potential raters. ICC values will be classified as follows: less than 0.5 indicates low reliability, 0.5 to 0.74 indicates moderate reliability, 0.75 to 0.9 indicates good reliability, and greater than 0.9 indicates excellent reliability. Confidence interval for the ICC will be reported to assess the precision of the reliability estimate. (18)

# 222 ETHICS AND DISSEMINATION

The study protocol was reviewed and approved by the Institutional Review Board of the
University of Hong Kong (HKU) / Hospital Authority Hong Kong West Cluster (HKWC) –
HKU/HA HKW IRB–UW 24-108. Informed consent was exempted.

The data collected in this study will be retrospective in nature, which had already been recorded for clinical purposes. All patient data will be fully de-identified prior to analysis, ensuring that privacy and confidentiality will not be breached. The findings of the study will be published in peer-reviewed academic journals and presented in abstract form at relevant scientific conferences.

# 231 STATUS AND TIMELINE OF THE STUDY

The study is currently in the evaluation phase, having successfully recruited a qualified panel of clinical microbiologists and infectious disease physicians in January 2024. These evaluators are actively reviewing the provided clinical scenarios. Preliminary analysis will be performed in March 2024. We aim to finalise data analysis by May 2024 and to have a complete report ready for peer review and publication by late May to June 2024.

# 237 RESULTS AND DISCUSSION

238 In this protocol, we hypothesise that analytical performance of AI chatbots in real-life clinical 239 scenarios could be objectively measured using a standardised assessment protocol and graded 240 by clinically experienced human evaluators. We also hypothesise that AI chatbots, when primed with specific medical knowledge and structural clinical scenarios, could generate 241 242 clinically relevant recommendations within the boundaries of the prompt template and the 243 scope of the provided clinical data. We further hypothesise that AI chatbots could assist 244 clinicians by providing accurate, comprehensive, and coherent analysis in clinical consultations, without posing medical harm. 245

246 We have identified several key limitations that bear consideration when interpreting this study. 247 One of the primary limitations is that the study design does not accommodate for the potential 248 of continued learning and adaptation by the AI chatbots over time. Advances in machine 249 learning suggest that generative AI performances could be improved with continued exposure 250 to clinical scenarios (21), a factor that our current protocol does not address. Additionally, our 251 protocol will rely on historical clinical data, which may not fully represent the dynamic and 252 often unpredictable nature of real-time clinical decision-making. The inherent variability and 253 emergent complexities of real-life clinical environments are difficult to replicate in a cross-254 sectional observational study, potentially limiting the generalisability of our findings.

The integrity of chatbot-generated responses is directly tied to the quality of the clinical data inputted. (22) Inaccuracies, inconsistencies, or gaps in the original clinical documents pose a significant risk of compromising the generative AI models, leading to suboptimal performance that may not reflect the systems' true capabilities. Furthermore, there are concerns regarding the evaluation scale utilised in this study, which has not been validated and may introduce subjective biases in the evaluation process.

The degree of expertise of human evaluators is another limitation. The study outcomes are dependent on the evaluators' proficiency and their interpretation of the generated responses. Selected evaluators' perspectives may not encapsulate the wide-ranging opinions and approaches that exist within the broader medical community, potentially leading to an evaluation that does not fully capture the diversity of clinical judgments.

To mitigate the limitations in the study design, we have implemented several strategic 266 267 interventions. Recognising the critical importance of data quality, we will institute a rigorous 268 data curation phase where clinical documents will be reviewed, cleaned, and standardised to 269 ensure AI chatbot operates on high-integrity data. To address the potential for evaluator bias, 270 we will introduce blinding procedures including evaluator blinding, scenario randomisation 271 and response randomisation. Moreover, we will select two diverse groups of evaluators to 272 encompass a broad spectrum of clinical viewpoints, ensuring our study reflects the varied 273 insights from both specialists and non-specialist doctors.

To conclude, this study will represent a significant step towards understanding the analytical potentials of AI chatbots in the clinical settings. While the initial results will provide valuable insights into the capabilities and limitations of AI chatbots in processing and analysing clinical data in a structured manner, the limitations identified must be carefully considered.

278 Contributors

EK-YC and TW-HC contributed to the conception and design of the study. EK-YC wrote thefirst manuscript draft with input from TW-HC. All authors contributed to the critical review

- and revision of the manuscript. All authors had full access to all the data in the study and had
- final responsibility for the decision to submit for publication.

#### **Declaration of interests**

The authors have disclosed that there are no competing financial interests or personal relationships that could be perceived as having influenced the findings or interpretations presented in this paper.

287 **Correspondence** should be addressed to TW-HC.

#### 288 Table. AI chatbot evaluation scale and rubric

Domains	1	2	3	4	5
Factual consistency	Unverified /	Insufficiently	Partially	Predominantly	Fully verified
	Non-factual	verified facts	verified facts	verified facts	facts
Comprehensiveness	Limited	Partial	Considerable	Extensive	Complete
	coverage	coverage	coverage	coverage	coverage
Coherence	Wholly	Substantially	Moderately	Minimally	Fully
	incoherent	incoherent	incoherent	incoherent	coherent
Medical harmfulness	Severely	Moderately	Mildly	Minimally	Harmless
	harmful	harmful	harmful	harmful	

289

# 290 **Figure legends**:

291 Figure 1. Materials and methods. AI: artificial intelligence.

292 Figure 2. Healthcare-specific standardised prompt template.

# 293 **References:**

Orrù G, Piarulli A, Conversano C, Gemignani A. Human-like problem-solving abilities
 in large language models using ChatGPT. Frontiers in Artificial Intelligence. 2023;6:1199350.

296	2. Howard A, Hope W, Gerada A. ChatGPT and antimicrobial advice: the end of the				
297	consulting infection doctor? The Lancet Infectious Diseases. 2023;23(4):405-6.				
298	3. Dyckhoff-Shen S, Koedel U, Brouwer MC, Bodilsen J, Klein M. ChatGPT fails				
299	challenging the recent ESCMID brain abscess guideline. Journal of Neurology. 2024:1-16.				
300	4. Schwartz IS, Link KE, Daneshjou R, Cortés-Penfield N. Black box warning: large				
301	language models and the future of infectious diseases consultation. Clinical Infectious Diseases.				
302	2023:ciad633.				
303	5. Maillard A, Micheli G, Lefevre L, Guyonnet C, Poyart C, Canouï E, et al. Can Chatbot				
304	Artificial Intelligence Replace Infectious Diseases Physicians in the Management of				
305	Bloodstream Infections? A Prospective Cohort Study. Clinical Infectious Diseases.				
306	2023:ciad632.				
307	6. Tang L, Sun Z, Idnay B, Nestor JG, Soroush A, Elias PA, et al. Evaluating large				
308	language models on medical evidence summarization. NPJ Digit Med. 2023;6(1):158.				
309	7. Best practices for prompt engineering with OpenAI API: OpenAI; 2024 [Available				
310	from: <u>https://help.openai.com/en/articles/6654000-best-practices-for-prompt-engineering-</u>				
311	with-openai-api.				
312	8. The Art of AI Prompt Crafting: A Comprehensive Guide for Enthusiasts: OpenAI; 2023				
313	[Available from: <u>https://community.openai.com/t/the-art-of-ai-prompt-crafting-a-</u>				
314	comprehensive-guide-for-enthusiasts/495144.				
315	9. Prompt engineering: OpenAI; 2023 [Available from:				
316	https://platform.openai.com/docs/guides/prompt-engineering.				
317	10. Prompt engineering techniques: Microsoft Corporation; 2023 [Available from:				
318	https://learn.microsoft.com/en-us/azure/ai-services/openai/concepts/advanced-prompt-				
319	engineering?pivots=programming-language-chat-completions.				
320	11. Török E, Moran E, Cooke F. Oxford handbook of infectious diseases and microbiology.				
321	2nd ed: Oxford University Press; 2016.				
322	12. Mitchell RN, Kumar V, Abbas AK, Aster JC. Pocket Companion to Robbins & Cotran				
323	Pathologic Basis of Disease E-Book. 9th ed: Elsevier Health Sciences; 2016.				
324	13. Sabatine MS. Pocket medicine (Pocket notebook series). 8th ed: Wolters Kluwer Health				
325	2022.				
326	Gilbert DN, Chambers HF, Saag MS, Pavia AT, Boucher HW. The Sanford guide to				
327	antimicrobial therapy 2022. Antimicrobial Therapy. 2022.				
328	15. API Reference: OpenAI; 2024 [Available from: <u>https://platform.openai.com/docs/api-</u>				
329	reference/introduction.				

330 16. Sullivan GM, Artino Jr AR. Analyzing and interpreting data from Likert-type scales.

Journal of graduate medical education. 2013;5(4):541-2.

- 332 17. Norman G. Likert scales, levels of measurement and the "laws" of statistics. Advances
  333 in health sciences education. 2010;15:625-32.
- Liu S, Wright AP, Patterson BL, Wanderer JP, Turer RW, Nelson SD, et al. Using AIgenerated suggestions from ChatGPT to optimize clinical decision support. Journal of the
  American Medical Informatics Association. 2023;30(7):1237-45.
- 337 19. Goodman RS, Patrinely JR, Stone CA, Zimmerman E, Donald RR, Chang SS, et al.
  338 Accuracy and reliability of chatbot responses to physician questions. JAMA network open.
  339 2023;6(10):e2336483-e.
- 340 20. Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, et al. Comparing physician
- and artificial intelligence chatbot responses to patient questions posted to a public social mediaforum. JAMA internal medicine. 2023.
- Feng J, Phillips RV, Malenica I, Bishara A, Hubbard AE, Celi LA, Pirracchio R.
  Clinical artificial intelligence quality improvement: towards continual monitoring and updating
  of AI algorithms in healthcare. npj Digital Medicine. 2022;5(1):66.
- Jain A, Patel H, Nagalapatti L, Gupta N, Mehta S, Guttula S, et al., editors. Overview
  and importance of data quality for machine learning tasks. Proceedings of the 26th ACM
  SIGKDD international conference on knowledge discovery & data mining; 2020.

349

# Prompt template

You an artificial intelligence assistant, with expert knowledge in clinical medicine, infectious diseases, clinical microbiology and virology.

Carefully examine and review the provided clinical scenario.

Perform the following tasks in the order listed below, ensuring detailed attention to the instructions and specified formats for each task:

1. \*\*Chronological Events\*\*:

Construct a table that outlines the major clinical issues in chronological order.

2. \*\*Clinical Problem List\*\*:

medRxiv preprint doi: https://doi.org/10.1191/1924.03.01.21308599; this version nosted March 2, 2034. The polyright holder for this preprint to 'active' or 'chronic' (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

3. \*\*Potential Life-Threatening Complications\*\*:

Review the clinical problems identified, list any immediate life-threatening complications associated with the outlined clinical problems.

4. \*\*Clinical Findings\*\*:

Construct a table categorizing the anticipated physical examination findings by organ systems.

5. \*\*Working Diagnoses\*\*:

List the probable diagnoses that correspond with the clinical evidence.

6. \*\*Relevant Investigations\*\*:

Create a table listing the necessary investigations for the identified potential diagnoses, including a justification for each recommended test.

7. \*\*Management Plan\*\*:

Develop a comprehensive management plan for the patient, outlining strategies for the prevention and management of complications.

8. \*\*Executive Summary\*\*:

Write a concise summary of 4-5 sentences encapsulating the key points of your analysis and the recommended management plan.

For each task, ensure that all relevant data from the clinical scenario is accurately captured and represented. Ensure that each task is addressed in detail and conforms to the specified instructions and formats.

# Figure 2

